Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study
新辅助吡咯替尼和曲妥珠单抗治疗HER2阳性乳腺癌早期无反应(NeoPaTHer):一项前瞻性、多中心、反应适应性研究的疗效、安全性和生物标志物分析
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02138-6
Wang, Fei; Wang, Yongjiu; Xiong, Bin; Yang, Zhenlin; Wang, Jingfen; Yao, Yumin; Yu, Lixiang; Fu, Qinye; Li, Liang; Zhang, Qiang; Zheng, Chao; Huang, Shuya; Liu, Liyuan; Liu, Chun; Sun, Huaibo; Mao, Beibei; Liu, Dong-Xu; Yu, Zhigang